NCT06803589 · Mayo Clinic
Growth Hormone for the Treatment of Gastroparesis
What this study is about
The purpose of this study is to determine whether treatment with Growth Hormone results in symptomatic improvement in patients with gastroparesis.
View original scientific description
The purpose of this study is to determine whether treatment with Growth Hormone results in symptomatic improvement in patients with gastroparesis.
Interventions
DRUG
Growth Hormone
Subjects will receive somapacitan-beco (Sogroya®) administered as a subcutaneous injection once weekly for 12 weeks. All participants will receive a fixed dose of 1.5 mg weekly, regardless of sex.
Primary outcome measures
Gastroparesis Cardinal Symptom Index (GCSI)
Time frame: Baseline, 4 weeks, 8 weeks, 12 weeks, 14 weeks
The Gastroparesis Cardinal Symptom Index (GCSI) is a questionnaire that assesses the severity of gastroparesis symptoms of: nausea, early satiety, postprandial fullness, and upper abdominal pain. Scores range from 0-none to 4-very severe.
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- Symptoms \> 6 months that have not responded satisfactorily to standard treatment.
- For gastroparesis: Gastroparesis Cardinal Symptom Index (GCSI) score of \>21
Exclusion criteria
- Known history of GH deficiency, hypothalamic or pituitary disease
- Prior use of GH therapy
- Age-adjusted low serum IGF1
- Women on oral estrogen therapy6
- Pregnancy or nursing
- History of malignant solid tumors
- Obesity (BMI \> 30)History of coronary and thromboembolic diseases.
- History of sarcoidosis
- History of pituitary surgery
- History of thyroid nodules.
- Any other condition, which in the opinion of the investigator would impede compliance or hinder completion of the study.
- Failure to give informed consent.
Where
- Phoenix, Arizona
- Scottsdale, Arizona
Related conditions & keywords
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Apr 16, 2026 · Source of record for eligibility and locations